Wuxi Apptec - WUXAY STOCK NEWS

WuXi AppTec (WuXi) has expanded its Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters in response to surging demand. This expansion includes the commissioning of two new peptide manufacturing plants at the Changzhou facility and the new Taixing site in China. The company's cutting-edge digital operation systems with automated solvent delivery optimize production consistency, minimize human errors, and reduce production cycle time. WuXi TIDES CRDMO platform provides integrated services for oligonucleotides, peptides, and conjugates, including both API and drug product from discovery to commercial stages. In 2023 alone, WuXi TIDES supported...

WuXi AppTec (WUXI) receives the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, highlighting their open-access and integrated platform supporting customers' work in the pharmaceutical and healthcare sector, with a vision to improve patients' quality of life.

WuXi AppTec announces its financial results for Q3 2023. Revenue grew 4.0% YoY to RMB29,541 million. Net profit increased 9.5% YoY to RMB8,076 million. Diluted EPS increased 18.7% YoY to RMB2.73. Free cash flow grew strongly by 32.5% YoY.

WuXi AppTec reports revenue of RMB9,908 million in Q2, up 6.7% YoY. Net profit increases 14.6% to RMB5,313 million. Diluted EPS increases 20.9% to RMB1.79. Free cash flow achieves RMB2,926 million for the first half.

WuXi AppTec reported a 5.8% increase in revenue year-over-year, reaching RMB8,964 million for Q1 2023. The net profit attributable to owners surged by 32.0% to RMB2,168 million, while diluted earnings per share (EPS) rose by 35.8% to RMB0.72. Adjusted non-IFRS net profit grew 14.1% to RMB2,342 million, and free cash flow turned positive at RMB1,682 million. Key business segments showed varying performance: WuXi Chemistry and WuXi Testing experienced revenue growth, while WuXi DDSU faced a significant revenue decline of 31.0%. The company continues to expand its global customer base, having added over 310 new customers.

WuXi AppTec reported a 71.8% increase in revenue year-over-year, reaching RMB39,355 million for 2022. Their net profit attributable to owners grew 72.9% to RMB8,814 million, with diluted EPS rising 63.0% to RMB2.82. The adjusted non-IFRS net profit surged 83.2% to RMB9,399 million. Operating cash flow improved by 133.6% to RMB10,230 million, with free cash flow turning positive. A cash dividend of RMB2,644 million will be distributed, constituting 30% of 2022 net profit. Despite challenges from COVID-19, WuXi expanded its customer base to over 5,950 active accounts, driving strong performance in its CRDMO and CTDMO business models.

WuXi AppTec has been awarded the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award by Frost & Sullivan, marking its sixth consecutive recognition. The award highlights WuXi AppTec's leadership and innovative services in the pharmaceutical and biotech sectors. The company's integrated CRDMO and CTDMO models enhance customer service value and address evolving healthcare demands. WuXi AppTec aims to strengthen its capabilities to support the development of groundbreaking therapies for patients worldwide.

WuXi AppTec reported a remarkable performance for Q3 2022, achieving a 77.8% year-over-year increase in revenue to RMB10,638 million. The net profit attributable to owners soared 209.1% year-over-year to RMB2,742 million, with diluted EPS rising 170.0% to RMB0.81. For the nine months ending September 30, 2022, revenue increased 71.9% year-over-year to RMB28,395 million, while net profit grew 107.1% to RMB7,378 million. Operating cash flow surged 142.1% to RMB7,431 million, showcasing robust operational execution.